ArticleJournal of nanobiotechnology2025
Bioengineered cardiovascular bypass grafts via in vivo self-assembly of scaffold-guided tubular tissue in rats.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effect of Apical Micro-Intervention on Pulp Vitality and Periodontal Regeneration Following Tooth Autotransplantation: A Clinical Outcome Study.International dental journal · 2026Article
- Constructing a biomimetic ECM protective barrier: a strategic interface design for urethral repair to mitigate foreign body reaction.Journal of nanobiotechnology · 2026Article
- Degradable scaffold-mediated synergistic matrix formation by endogenous cells: an in vivo manufacturing strategy for off-the-shelf vascular grafts to address clinical shortages.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cardiovascular bypass grafting remains a crucial therapeutic approach for complex atherosclerotic diseases. However, the clinical application of traditional grafts is hampered by limited autologous vessel availability, while the translational potential of fully cellular self-assembled vascular grafts is constrained by their prolonged fabrication. Here, we present a scaffold-guided in vivo tubular tissue self-assembly strategy to rapidly engineer functional cardiovascular bypass grafts. Using 3D-printed biodegradable scaffolds implanted subcutaneously in SD rats, we generated bioengineered tubular vascular constructs (BTCs) rich in host cells and extracellular matrix within 2 weeks. BTC exhibited biophysical and biochemical properties highly analogous to the native abdominal aorta. When used as interpositional grafts in the abdominal aorta, the BTCs demonstrated excellent patency, blood flow velocity, vascular reactivity, compliance, and histological architecture comparable to those of the native vessel over a 24-week implantation period. Our method significantly shortens the fabrication time of bioengineered vessels-from several months to two weeks-thereby aligning with the critical time window required for elective cardiovascular bypass surgery. Moreover, all materials used in this study are clinically approved, which facilitates future clinical translation. This work establishes a practical and scalable platform for the rapid, "off-the-shelf" production of bioengineered cardiovascular grafts through stable scaffold-guided in vivo tissue formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.